Is this the end of costly and harmful pharmaceutical advertising?
Direct-to-consumer pharmaceutical advertising is under increasing political pressure, with bipartisan legislation being introduced to ban or restrict the practice, and states considering bills to deny tax deductions for pharmaceutical advertising expenses.
Direct-to-consumer pharmaceutical advertising is under increasing political pressure, with bipartisan legislation being introduced to ban or restrict the practice, and states considering bills to deny tax deductions for pharmaceutical advertising expenses.
Direct-to-consumer pharmaceutical advertising is under increasing political pressure, with bipartisan legislation being introduced to ban or restrict the practice, and states considering bills to deny tax deductions for pharmaceutical advertising expenses.
The full story continues on The Hill.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.